Vivos Therapeutics (VVOS) Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Current Assets data on file, last reported at $4.8 million in Q1 2026.

• On a quarterly basis, Current Assets rose 33.6% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 33.6% increase from a year earlier, with the FY2025 full-year figure at $4.4 million, down 41.34% from the prior year.
• Current Assets for Q1 2026 stood at $4.8 million, up from $4.4 million in the prior quarter.
• Over the last five years, Current Assets for VVOS reached as high as $21.6 million in Q1 2022 and fell as low as $2.0 million in Q3 2023.
• Historically, Current Assets has averaged $7.2 million across 5 years, with a median of $5.8 million in 2025.
• Across the five-year window, Current Assets tumbled 80.15% in 2022 and jumped 272.75% in 2024, its largest moves.
• Year by year, Current Assets stood at $5.4 million in 2022, then tumbled by 54.63% to $2.5 million in 2023, then surged by 203.66% to $7.5 million in 2024, then tumbled by 41.34% to $4.4 million in 2025, then advanced by 9.92% to $4.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $4.8 million in Q1 2026, $4.4 million in Q4 2025, and $5.8 million in Q3 2025.